Cargando…

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection

Detalles Bibliográficos
Autor principal:	Van Der Ryst, Elna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456946/ https://www.ncbi.nlm.nih.gov/pubmed/26097475 http://dx.doi.org/10.3389/fimmu.2015.00277

Ejemplares similares

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
por: Jubb, Becky, et al.
Publicado: (2019)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
por: Cooper, David A., et al.
Publicado: (2014)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: López-Huertas, María Rosa, et al.
Publicado: (2017)

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens
por: Lewis, ME, et al.
Publicado: (2021)

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
por: Ochoa-Callejero, Laura, et al.
Publicado: (2013)

Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV
por: Matt, Stephanie M., et al.
Publicado: (2021)

In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection
por: Gramegna, Pasqua, et al.
Publicado: (2011)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
por: Roche, Michael, et al.
Publicado: (2011)

A Topical Microbicide Gel Formulation of CCR5 Antagonist Maraviroc Prevents HIV-1 Vaginal Transmission in Humanized RAG-hu Mice
por: Neff, C. Preston, et al.
Publicado: (2011)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc
por: Lewis, ME, et al.
Publicado: (2021)

The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis
por: Le, Ngoc Dung, et al.
Publicado: (2022)

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials
por: Lewis, Marilyn, et al.
Publicado: (2018)

A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure
por: Ishihara, Yasuhiro, et al.
Publicado: (2022)

Stochastic Model of In-Vivo X4 Emergence during HIV Infection: Implications for the CCR5 Inhibitor Maraviroc
por: Savkovic, Borislav, et al.
Publicado: (2012)

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice
por: Ferrero, Maximiliano Ruben, et al.
Publicado: (2021)

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
por: Roche, Michael, et al.
Publicado: (2013)

CCR5 and HIV Infection, a View from Brussels
por: Parmentier, Marc
Publicado: (2015)

Genetic Polymorphism at CCL5 Is Associated With Protection in Chagas’ Heart Disease: Antagonistic Participation of CCR1(+) and CCR5(+) Cells in Chronic Chagasic Cardiomyopathy
por: Batista, Angelica Martins, et al.
Publicado: (2018)

Hippocampal CCR5/RANTES Elevations in a Rodent Model of Post-Traumatic Stress Disorder: Maraviroc (a CCR5 Antagonist) Increases Corticosterone Levels and Enhances Fear Memory Consolidation
por: Merino, José Joaquín, et al.
Publicado: (2020)

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
por: Casagrande, Naike, et al.
Publicado: (2019)

Filling the Gaps in Antagonist CCR5 Binding, a Retrospective and Perspective Analysis
por: Amerzhanova, Yerkezhan, et al.
Publicado: (2022)

A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics
por: Karris, Maile Y., et al.
Publicado: (2016)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor
por: Jiang, Xiaowei, et al.
Publicado: (2015)

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
por: Mohamed, Hager, et al.
Publicado: (2022)

In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability
por: Casagrande, Naike, et al.
Publicado: (2021)

Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy
por: Kwiatkowski, Klaudia, et al.
Publicado: (2020)

Localization-Specific Expression of CCR1 and CCR5 by Mast Cell Progenitors
por: Salomonsson, Maya, et al.
Publicado: (2020)

CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab
por: Chang, Xiao L., et al.
Publicado: (2021)

Blocking the CCL5–CCR5 Axis Using Maraviroc Promotes M1 Polarization of Macrophages Cocultured with Irradiated Hepatoma Cells
por: Zhuang, Yuan, et al.
Publicado: (2021)

Short Communication: HIV-1 Variants That Use Mouse CCR5 Reveal Critical Interactions of gp120's V3 Crown with CCR5 Extracellular Loop 1
por: Platt, Emily J., et al.
Publicado: (2015)

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
por: Gulick, Roy M., et al.
Publicado: (2014)

The Dual Role of CCR5 in the Course of Influenza Infection: Exploring Treatment Opportunities
por: Ferrero, Maximiliano Ruben, et al.
Publicado: (2022)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

HIV-1 and SIV Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T Follicular Helper Cells
por: Xu, Yin, et al.
Publicado: (2017)

Editorial: CCR5: A receptor at the center stage in infection
por: Ellwanger, Joel Henrique, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m3cjjdc864mm2mb3ii5nlrkqr1